Navigation Links
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:10/14/2010

ow and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of Oct. 14, 2010 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.   Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. Array BioPharma and Amgen Partner in Type 2 Diabetes
3. Amgen to Present at Lazard Capital Healthcare Conference
4. Amgen Announces Webcast of 2009 Third Quarter Financial Results
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
8. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
9. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
10. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
11. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , SAN DIEGO, Aug. 6 SEQUENOM, Inc. ... ended June 30, 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ... Total revenue for the second quarter of 2009 was $9.2 million, ... the comparable period last year was primarily due to softness in capital expenditure ...
... ... Launch Of Its New And Improved Website. The New Site Provides Users With A ... Functionality And Navigation. The Site Also Offers An Expanded Service Description For Each Of ... ...
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
Cached Biology Technology:SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 10One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... FRANCISCO - Scientists from the Department of Energy,s Pacific ... energy-related research at the 2012 American Geophysical Union Fall ... 7 at the Moscone Convention Center in San Francisco. ... measuring the resources needed to grow algae for biofuel ...
... The William R. Kenan, Jr. Charitable Trust has awarded ... $1 million to support the institute,s education outreach programs ... single gift to date in support of Scripps Florida,s ... Kenan Trust support, the new four-year grant will run ...
... study may help scientists produce better climate-resistant corn and other ... that we are what we eat. Kansas State University ... used to study and prioritize the genes in humans, it ... plants. These genes control quantitate traits in plants, such as ...
Cached Biology News:Sunshine, biofuel and the tides, oh my! 2Sunshine, biofuel and the tides, oh my! 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3
Human Cell Line Slides...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Biology Products: